UK spin‑out speeds up development and reduces animal testing
News
Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
Boehringer Ingelheim reports significant reductions in weight
Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
Partnership to support selection of first neoantigen therapy candidate
BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
Collaboration aims to create integrated platform from discovery to IND submission
Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
Lead asset shows systemic, dose‑dependent anti‑tumour activity
Theolytics announces first patient dosed in the Octopod‑IP trial
US study marks company’s second clinical trial of ovarian cancer therapy
UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
Clesrovimab is first monoclonal antibody offering a single fixed dose for infants
Saphnelo approved in the US for subcutaneous self‑administration
Greater flexibility for people with systemic lupus erythematosus
Transgene completes randomisation in phase 2 trial of tg4050
Company expects two‑year dfs data by q1 2028
Bayer wins MHRA approval for Kerendia in heart failure
New authorisation offers additional option for patients with lvef ≥40%
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
Partnership to develop next‑generation T‑cell engagers for solid tumours
Kainova expands DT 7012 trial into Europe
First patient dosed as DOMISOL study grows beyond Australia
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
Study expands development of the antibody into hepatocellular carcinoma
FDA approves new high dose Spinraza regimen for SMA
Updated dosing offers meaningful clinical benefit
